Prediction of Pathologic Complete Response for Rectal Cancer Based on Pretreatment Factors Using Machine Learning

被引:2
|
作者
Chen, Kevin A. [1 ]
Goffredo, Paolo [2 ]
Butler, Logan R. [1 ]
Joisa, Chinmaya U. [3 ]
Guillem, Jose G. [1 ]
Gomez, Shawn M. [3 ]
Kapadia, Muneera R. [1 ,4 ]
机构
[1] Univ N Carolina, Dept Surg, Div Gastrointestinal Surg, Chapel Hill, NC USA
[2] Univ Minnesota, Dept Surg, Div Colorectal Surg, Minneapolis, MN USA
[3] Univ N Carolina, Joint Dept Biomed Engn, Chapel Hill, NC USA
[4] Univ N Carolina, Dept Surg, Div Gastrointestinal Surg, 100 Manning Dr,Burnett Womack Bldg,Suite 4038, Chapel Hill, NC 27599 USA
基金
美国国家卫生研究院;
关键词
Artificial intelligence; Machine learning; Pathological complete response; Rectal cancer; PREOPERATIVE CHEMORADIOTHERAPY; NEOADJUVANT CHEMORADIOTHERAPY; CHEMORADIATION THERAPY; TUMOR-REGRESSION; OUTCOMES;
D O I
10.1097/DCR.0000000000003038
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND: Pathologic complete response after neoadjuvant therapy is an important prognostic indicator for locally advanced rectal cancer and may give insights into which patients might be treated nonoperatively in the future. Existing models for predicting pathologic complete response in the pretreatment setting are limited by small data sets and low accuracy. OBJECTIVE: We sought to use machine learning to develop a more generalizable predictive model for pathologic complete response for locally advanced rectal cancer. DESIGN: Patients with locally advanced rectal cancer who underwent neoadjuvant therapy followed by surgical resection were identified in the National Cancer Database from years 2010 to 2019 and were split into training, validation, and test sets. Machine learning techniques included random forest, gradient boosting, and artificial neural network. A logistic regression model was also created. Model performance was assessed using an area under the receiver operating characteristic curve. SETTINGS: This study used a national, multicenter data set. PATIENTS: Patients with locally advanced rectal cancer who underwent neoadjuvant therapy and proctectomy. MAIN OUTCOME MEASURES: Pathologic complete response defined as T0/xN0/x. RESULTS: The data set included 53,684 patients. Pathologic complete response was experienced by 22.9% of patients. Gradient boosting showed the best performance with an area under the receiver operating characteristic curve of 0.777 (95% CI, 0.7730.781), compared with 0.684 (95% CI, 0.680.688) for logistic regression. The strongest predictors of pathologic complete response were no lymphovascular invasion, no perineural invasion, lower CEA, smaller size of tumor, and microsatellite stability. A concise model including the top 5 variables showed preserved performance. LIMITATIONS: The models were not externally validated. CONCLUSIONS: Machine learning techniques can be used to accurately predict pathologic complete response for locally advanced rectal cancer in the pretreatment setting. After fine-tuning a data set including patients treated nonoperatively, these models could help clinicians identify the appropriate candidates for a watch-and-wait strategy. See Video Abstract.
引用
收藏
页码:387 / 397
页数:11
相关论文
共 50 条
  • [21] Rectal cancer: Prediction of pathologic complete response by artificial intelligence-based evaluation of pretherapeutic MRI and histology
    Rink, Andreas D.
    COLOPROCTOLOGY, 2022, 44 (03) : 203 - 204
  • [22] Predictors and risk factors of Pathologic Complete Response Following Neoadjuvant Chemoradiotherapy for Rectal Cancer
    Tan, Yinuo
    Fu, Dongliang
    Jiang, Kai
    Kong, Xiangxing
    Yuan, Ying
    Ding, Kefeng
    ANNALS OF ONCOLOGY, 2018, 29
  • [23] Correction to: Predicting pathologic complete response in locally advanced rectal cancer patients after neoadjuvant therapy: a machine learning model using XGBoost
    Xijie Chen
    Wenhui Wang
    Junguo Chen
    Liang Xu
    Xiaosheng He
    Ping Lan
    Jiancong Hu
    Lei Lian
    International Journal of Colorectal Disease, 2022, 37 : 1919 - 1919
  • [24] Do not expect an endoluminal complete response to identify a pathologic complete response in rectal cancer!
    Gheller, Alexandre
    Neiva, Guilherme Inacio Bertoldo de Melo e Patriarca da Silva
    de Araujo Neto, Mario Nobrega
    Lyrio, Fernando Gonsalves
    Basilio, Dunya Bachour
    da Costa, Marilia Cristina Roda
    Mourao, Douglas Vieira
    de Oliveira, Paulo Gonsalves
    de Sousa, Joao Batista
    CLINICS, 2025, 80
  • [25] Interpretable machine learning for predicting pathologic complete response in patients treated with chemoradiation therapy for rectal adenocarcinoma
    Wang, Du
    Lee, Sang Ho
    Geng, Huaizhi
    Zhong, Haoyu
    Plastaras, John
    Wojcieszynski, Andrzej
    Caruana, Richard
    Xiao, Ying
    FRONTIERS IN ARTIFICIAL INTELLIGENCE, 2022, 5
  • [26] Clinical and molecular diagnosis of pathologic complete response in rectal cancer
    Patel, Prachi M.
    Harris, Kelly
    Huerta, Sergio
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2015, 15 (11) : 1505 - 1516
  • [27] Pathologic complete response in patients with neoadjuvant chemoradiotherapy for rectal cancer
    Espinola M, Daniella
    Molina P, Maria E.
    Bellolio R, Felipe
    Gellona, Jose, V
    Bustos C, Mariza
    Zuniga D, Alvaro
    REVISTA CHILENA DE CIRUGIA, 2013, 65 (04): : 333 - 337
  • [28] Complete pathologic response after preoperative rectal cancer chemoradiotherapy
    Ciccocioppo, Anthony
    Stephens, Jacqueline H.
    Hewett, Peter J.
    Rieger, Nicholas A.
    ANZ JOURNAL OF SURGERY, 2009, 79 (06) : 481 - 484
  • [29] Characteristics of pathologic complete response for locally advanced rectal cancer
    Cloos, Adam J.
    Schissel, Makayla
    Batra, Rishi
    Donahue, Steven R.
    Wenos, Chelsea D.
    Kumar, Terrence
    Leinicke, Jennifer A.
    Thompson, Jon S.
    Langenfeld, Sean J.
    AMERICAN JOURNAL OF SURGERY, 2023, 226 (06): : 873 - 877
  • [30] Predictors and Risk Factors of Pathologic Complete Response Following Neoadjuvant Chemoradiotherapy for Rectal Cancer: A Population-Based Analysis
    Tan, Yinuo
    Fu, Dongliang
    Liu, Dan
    Kong, Xiangxing
    Jiang, Kai
    Chen, Liubo
    Yuan, Ying
    Ding, Kefeng
    FRONTIERS IN ONCOLOGY, 2019, 9